Isfort R J, LeBoeuf R A
CP&RSD/HSD, Proctor & Gamble Company, Miami Valley Laboratories, Cincinnati, OH 45253-8707, USA.
Crit Rev Oncog. 1995;6(3-6):251-60. doi: 10.1615/critrevoncog.v6.i3-6.30.
Neoplastic transformation is a multistep process that can be modeled in vitro using Syrian hamster embryo (SHE) cells. SHE cells multistage transformation involves several intermediate stages, including morphological transformation, immortality, acquisition of tumorigenicity, and malignant progression. Analysis of the molecular alterations that occur at each stage indicated that morphological transformation results from both carcinogen-induced irreversible chromosomal/genetic mutations and reversible genetic events, including altered DNA methylation. Morphological transformation results from a block in the cellular differentiation of progenitor and determined stem-like cells in the SHE cell population via alternation in the expression of the H19 tumor suppressor gene and other genes. Immortality results from genetic mutations in growth factor responsiveness, including loss of growth suppression by TGF beta and autocrine growth factor production, and genomic stability, resulting in genomic instability and an increased mutation rate. Acquisition of tumorigenicity involves loss of tumor suppressor gene function, altered mitogenic signal transduction, mutation of oncogenes, acquisition of anchorage independent growth, and chromosomal aberrations. Malignant progression is associated with alterations in extracellular matrix growth characteristics, alterations in cytoskeleton structure, elevated fibrinolytic activity, secretion of proteases, and changes in extracellular matrix protein secretion. Together, these changes model the alterations observed during in vivo neoplastic transformation and possibly explain why the SHE assay, as a carcinogen screening tool, is able to identify carcinogens with a 80 to 85% accuracy.
肿瘤转化是一个多步骤过程,可在体外使用叙利亚仓鼠胚胎(SHE)细胞进行模拟。SHE细胞的多阶段转化涉及几个中间阶段,包括形态转化、永生化、致瘤性获得和恶性进展。对每个阶段发生的分子改变的分析表明,形态转化是由致癌物诱导的不可逆染色体/基因突变以及可逆遗传事件引起的,包括DNA甲基化改变。形态转化是由于SHE细胞群体中祖细胞和已确定的干细胞样细胞的细胞分化受阻,这是通过H19肿瘤抑制基因和其他基因表达的改变实现的。永生化是由生长因子反应性的基因突变导致的,包括转化生长因子β对生长抑制的丧失和自分泌生长因子的产生,以及基因组稳定性的改变,导致基因组不稳定和突变率增加。致瘤性的获得涉及肿瘤抑制基因功能的丧失、有丝分裂信号转导的改变、癌基因的突变、锚定非依赖性生长的获得以及染色体畸变。恶性进展与细胞外基质生长特性的改变、细胞骨架结构的改变、纤维蛋白溶解活性的升高、蛋白酶的分泌以及细胞外基质蛋白分泌的变化有关。总之,这些变化模拟了体内肿瘤转化过程中观察到的改变,并可能解释了为什么SHE试验作为一种致癌物筛选工具,能够以80%至85%的准确率识别致癌物。